All known subtypes of IFN- alpha show the same antiviral antiparasitic, antiproliferative activities. IFN-alpha forms are produced by monocytes/macrophages, lymphoblastoid cells, fibroblasts, and a number of different cell types following induction by viruses, nucleic acids, glucocorticoid hormones, and low-molecular weight substances. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. IFN-alpha and IFN-beta are thought to bind to the same receptor. Signal transduction mechanisms elicited after binding of IFN-alpha to its receptors involves tyrosine phosphorylation (see also: PTK; protein tyrosine kinase) of various non-receptor tyrosine kinases belonging to the Janus kinases.
Product Name- Recombinant Human IFNA1 (IFN-alpha1)
Aliases- Interferon alpha-D, IFN-alpha-1/13, LeIF D, IFNA13
Formulation- Lyophilized from a 0.2 µm filtered solution in Tris and NaCl (pH 8.0)
Endotoxin Level- <1.0 EU/µg of recombinant protein as determined by the LAL method.
Storage Condition- The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at +2° to +8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity.
Avoid repeated freeze/thaw cycles.